Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Orelabrutinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Beijing InnoCare Pharma Tech Co., Ltd. (InnoCare Pharma)
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Orelabrutinib is a once-daily tablet for certain B-cell blood cancers: chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). It was discovered by InnoCare Pharma, a company listed in Hong Kong and Shanghai, and is sold in China as 宜诺凯 (Yinuokai®). The Chinese marketing licence is held by 北京诺诚健华医药科技有限公司 (Beijing InnoCare Pharma Tech Co., Ltd.). In Singapore and Australia the same medicine carries the name Hibruka®.
China's National Medical Products Administration (NMPA) first gave it conditional approval on 25 December 2020 and has added uses since then. It is now approved in China for adults with:
Which of these fits a particular patient, and when, is a decision for the treating haematologist or haemato-oncologist. You can see other imported medicines for these cancers in our lymphoma treatment section.
B cells pass growth and survival signals through a pathway called the B-cell receptor pathway. An enzyme in that chain, Bruton's tyrosine kinase (BTK), stays overactive in many B-cell cancers and helps the abnormal cells keep multiplying. This medicine binds to BTK permanently and switches it off, which slows or stops those cells. It was designed to hit BTK very selectively, so that fewer other enzymes in the body are affected.
Untreated CLL/SLL: a phase 3 trial in China (NCT04578613) randomised 192 adults to this tablet or to chemoimmunotherapy (a chemotherapy tablet plus an antibody drip). After a median of 21.4 months:
Mantle cell lymphoma after earlier treatment: in two single-arm studies with 129 patients taking 150 mg once a day, an independent review found that 76.0% responded and 35.7% had a complete response.
Marginal zone lymphoma after earlier treatment: among 90 patients with centrally confirmed MZL, 58.9% responded (11.1% completely). The median response lasted 34.3 months, and 82.8% were free of progression at one year.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Who should not take it: people with severe liver impairment, and anyone who has had a serious allergic reaction to the medicine or its ingredients. The safety figures below come from 630 patients with blood cancers who took it on its own in clinical trials.
Common side effects in patients with mantle cell lymphoma (129 people) were low platelets (27.9%), anaemia (25.6%), colds and other upper airway infections (24.8%), low neutrophils (22.5%), rash (21.7%), diarrhoea (20.2%), high blood sugar (20.2%), high blood pressure (19.4%) and pneumonia (18.6%).
Other points: the liver enzyme CYP3A breaks it down. Strong or moderate blockers of this enzyme (some antifungals, antibiotics and HIV medicines) mean a lower dose, and strong boosters (such as some epilepsy medicines and St John's wort) should be avoided, so share a full medicine list with the doctor. Women who could become pregnant should use effective contraception during treatment and for at least 1 month afterwards; men should avoid fathering a child during treatment and for 3 months afterwards. Breastfeeding is not advised during treatment and for at least 2 weeks after the last dose. Safety in children has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets are brought in for one named patient, through the patient or the treating hospital, under India's rules on importing unapproved medicines for personal use. These papers are usually needed:
Once we have checked a valid prescription and, where required, the import permit has been issued.
No. CDSCO has not approved it, which means no Indian chemist can sell it. Regulators that have cleared it are those of China, Singapore (for mantle cell and marginal zone lymphoma) and Australia (provisional approval for mantle cell lymphoma). The US FDA has not approved it, and we found no European approval.
Doctors can still request it through the Named Patient Program (NPP), which lets a medicine without Indian registration be imported for a single patient on prescription. For CLL, families also ask us about lisaftoclax, a China-approved CLL tablet that works in a different way.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets are kept in their sealed original bottles and stored as directed on the pack; the Australian label asks for storage below 30°C, protected from light, with the lid closed. Parcels travel under temperature-controlled shipping which keeps the bottles away from high heat during transit. At the usual 150 mg dose a patient takes three tablets a day, about 90 a month, and we time each shipment so the next month's tablets arrive before the current bottle runs out. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
BTK treatment is taken every day, often for years, so a steady monthly supply matters more than a one-off delivery. With the paperwork complete, deliveries go to the cities named here and to many other places.
Lymphoma and CLL clinics in Delhi can get the tablets quickly, since every parcel leaves from our New Delhi base.
Haemato-oncologists in Mumbai can email the biopsy report and prescription, and we deliver to the home or the hospital pharmacy.
For families in Bangalore, we share a written quote and the expected arrival date before anything is ordered.
Patients in Chennai on long-term BTK treatment can have each month's supply timed around their blood-count visits.
Doctors in Hyderabad treating mantle cell or marginal zone lymphoma can request the tablets once the diagnosis is documented.
For Kolkata and the north-east, monthly parcels are couriered from Delhi with tracking details sent by message.
Families in Pune can set up a repeat supply so that the once-daily dose is never interrupted.
Haematologists in Ahmedabad can send the hepatitis B result and treatment summary, and we tell them if any paper is still missing.
Patients followed up in Vellore can have the bottles delivered to the hospital to match their review dates.
Haematologists in Chandigarh who follow patients from across the northern states can have the next bottle dispatched before the review date.
In Lucknow, families choose between home delivery and delivery to the treating cancer centre.
For patients across Kerala, parcels go to Kochi, Thrissur or the town closest to home.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 20 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message